Opioid Induced Constipation (OIC) Drugs Market Report – Research, Industry Analysis Reports and Market Demands

Global Opioid Induced Constipation (OIC) Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Opioid Induced Constipation (OIC) Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Lubiprostone
- 1.3.3 Methyl Naltrexone Bromide
- 1.3.4 Naldemedine
- 1.3.5 Alvimopan
- 1.3.6 Others
1.4 Market Analysis Route of Administration
- 1.4.1 Overview: Global Opioid Induced Constipation (OIC) Drugs Consumption Value Route of Administration: 2021 Versus 2025 Versus 2032
- 1.4.2 Oral Formulations
- 1.4.3 Injectable Formulations
- 1.4.4 Suppositories / Enemas
- 1.4.5 Other
1.5 Market Analysis Chemical Class
- 1.5.1 Overview: Global Opioid Induced Constipation (OIC) Drugs Consumption Value Chemical Class: 2021 Versus 2025 Versus 2032
- 1.5.2 Peripheral µ-opioid Receptor Antagonists,
- 1.5.3 Prokinetic Agents
- 1.5.4 Bulk-forming Laxatives
- 1.5.5 Other
1.6 Market Analysis by Application
- 1.6.1 Overview: Global Opioid Induced Constipation (OIC) Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospital Pharmacies
- 1.6.3 Retail Pharmacies
- 1.6.4 Online Pharmacies
1.7 Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecast
- 1.7.1 Global Opioid Induced Constipation (OIC) Drugs Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Opioid Induced Constipation (OIC) Drugs Sales Quantity (2021-2032)
- 1.7.3 Global Opioid Induced Constipation (OIC) Drugs Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Opioid Induced Constipation (OIC) Drugs by Manufacturer

3.1 Global Opioid Induced Constipation (OIC) Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Opioid Induced Constipation (OIC) Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Opioid Induced Constipation (OIC) Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Opioid Induced Constipation (OIC) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Opioid Induced Constipation (OIC) Drugs Manufacturer Market Share in 2025
- 3.4.3 Top 6 Opioid Induced Constipation (OIC) Drugs Manufacturer Market Share in 2025
3.5 Opioid Induced Constipation (OIC) Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Opioid Induced Constipation (OIC) Drugs Market: Region Footprint
- 3.5.2 Opioid Induced Constipation (OIC) Drugs Market: Company Product Type Footprint
- 3.5.3 Opioid Induced Constipation (OIC) Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Opioid Induced Constipation (OIC) Drugs Market Size by Region
- 4.1.1 Global Opioid Induced Constipation (OIC) Drugs Sales Quantity by Region (2021-2032)
- 4.1.2 Global Opioid Induced Constipation (OIC) Drugs Consumption Value by Region (2021-2032)
- 4.1.3 Global Opioid Induced Constipation (OIC) Drugs Average Price by Region (2021-2032)
4.2 North America Opioid Induced Constipation (OIC) Drugs Consumption Value (2021-2032)
4.3 Europe Opioid Induced Constipation (OIC) Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Consumption Value (2021-2032)
4.5 South America Opioid Induced Constipation (OIC) Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Opioid Induced Constipation (OIC) Drugs Sales Quantity by Type (2021-2032)
5.2 Global Opioid Induced Constipation (OIC) Drugs Consumption Value by Type (2021-2032)
5.3 Global Opioid Induced Constipation (OIC) Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Opioid Induced Constipation (OIC) Drugs Sales Quantity by Application (2021-2032)
6.2 Global Opioid Induced Constipation (OIC) Drugs Consumption Value by Application (2021-2032)
6.3 Global Opioid Induced Constipation (OIC) Drugs Average Price by Application (2021-2032)

7 North America

7.1 North America Opioid Induced Constipation (OIC) Drugs Sales Quantity by Type (2021-2032)
7.2 North America Opioid Induced Constipation (OIC) Drugs Sales Quantity by Application (2021-2032)
7.3 North America Opioid Induced Constipation (OIC) Drugs Market Size by Country
- 7.3.1 North America Opioid Induced Constipation (OIC) Drugs Sales Quantity by Country (2021-2032)
- 7.3.2 North America Opioid Induced Constipation (OIC) Drugs Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Opioid Induced Constipation (OIC) Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Opioid Induced Constipation (OIC) Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Opioid Induced Constipation (OIC) Drugs Market Size by Country
- 8.3.1 Europe Opioid Induced Constipation (OIC) Drugs Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Opioid Induced Constipation (OIC) Drugs Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Size by Region
- 9.3.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Opioid Induced Constipation (OIC) Drugs Sales Quantity by Type (2021-2032)
10.2 South America Opioid Induced Constipation (OIC) Drugs Sales Quantity by Application (2021-2032)
10.3 South America Opioid Induced Constipation (OIC) Drugs Market Size by Country
- 10.3.1 South America Opioid Induced Constipation (OIC) Drugs Sales Quantity by Country (2021-2032)
- 10.3.2 South America Opioid Induced Constipation (OIC) Drugs Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market Size by Country
- 11.3.1 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Opioid Induced Constipation (OIC) Drugs Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Opioid Induced Constipation (OIC) Drugs Market Drivers
12.2 Opioid Induced Constipation (OIC) Drugs Market Restraints
12.3 Opioid Induced Constipation (OIC) Drugs Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Opioid Induced Constipation (OIC) Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Opioid Induced Constipation (OIC) Drugs
13.3 Opioid Induced Constipation (OIC) Drugs Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Opioid Induced Constipation (OIC) Drugs Typical Distributors
14.3 Opioid Induced Constipation (OIC) Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Opioid Induced Constipation (OIC) Drugs market size was valued at US$ 2974 million in 2025 and is forecast to a readjusted size of US$ 4031 million by 2032 with a CAGR of 4.5% during review period.
Opioid Induced Constipation (OIC) refers to constipation symptoms induced by the prolonged use of opioid analgesics such as morphine, fentanyl, and oxycodone. This side effect is particularly common among chronic pain patients and significantly impacts their quality of life. To address this issue, various OIC drugs have been developed, including peripheral µ-opioid receptor antagonists (PAMORAs), prokinetic agents, osmotic or bulk-forming laxatives, stimulant laxatives, and combination therapies. These drugs alleviate or treat constipation symptoms caused by opioid use through different mechanisms of action.In 2024, global Opioid Induced Constipation (OIC) Drugs production reached approximately 277.5 m units , with an average global market price of around US$ 10 perunit.The average gross profit margin of this product is 37%.
The accelerating global aging process and the increasing number of chronic disease patients, especially cancer patients and those undergoing long-term analgesic treatment, have led to a rise in opioid use, thereby increasing the incidence of OIC. Moreover, the growing attention of medical institutions to patients' quality of life has driven the demand for OIC treatment drugs. The development and launch of new drugs, such as Naldemedine, have introduced new treatment options to the market, further promoting its development.
Despite the growing market demand, the high cost of OIC drugs remains a major challenge for patients and healthcare systems. Additionally, some drugs may have side effects, such as diarrhea and nausea, affecting patient compliance. In certain regions, especially in China, treatment options for OIC are limited, primarily relying on adjusting opioid doses or using traditional laxatives, which restricts further market development.
As patients place more emphasis on quality of life, medical institutions' awareness of OIC has increased, driving the use of OIC drugs. Particularly in cancer treatment and chronic pain management, the demand for OIC drugs continues to grow. Furthermore, the increasing demand for personalized treatment has driven the research and application of OIC drugs tailored to different patient groups.
The production of OIC drugs involves various raw materials, including active pharmaceutical ingredients (APIs), excipients, and packaging materials. The production of APIs requires high-purity chemical raw materials and complex synthesis processes to ensure the efficacy and safety of the drugs. Excipients, such as fillers and stabilizers, influence the stability of the drugs and the patient's experience. The choice of packaging materials relates to the storage and transportation conditions of the drugs. Therefore, the quality and supply stability of raw materials are crucial to the production of OIC drugs.
This report is a detailed and comprehensive analysis for global Opioid Induced Constipation (OIC) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Opioid Induced Constipation (OIC) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2021-2032
Global Opioid Induced Constipation (OIC) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2021-2032
Global Opioid Induced Constipation (OIC) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Dose), 2021-2032
Global Opioid Induced Constipation (OIC) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (USD/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Opioid Induced Constipation (OIC) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Opioid Induced Constipation (OIC) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Opioid Induced Constipation (OIC) Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Market segment Route of Administration
Oral Formulations
Injectable Formulations
Suppositories / Enemas
Other
Market segment Chemical Class
Peripheral µ-opioid Receptor Antagonists,
Prokinetic Agents
Bulk-forming Laxatives
Other
Market segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Major players covered
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Bausch Health
Zentiva
Orifarm A/S
Viatris
Endo International
Zhengdatianqing
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Opioid Induced Constipation (OIC) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Opioid Induced Constipation (OIC) Drugs, with price, sales quantity, revenue, and global market share of Opioid Induced Constipation (OIC) Drugs from 2021 to 2026.
Chapter 3, the Opioid Induced Constipation (OIC) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Opioid Induced Constipation (OIC) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Opioid Induced Constipation (OIC) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Opioid Induced Constipation (OIC) Drugs.
Chapter 14 and 15, to describe Opioid Induced Constipation (OIC) Drugs sales channel, distributors, customers, research findings and conclusion.

Buy now